Laurie Ozelius

List of Publications by Year
in descending order

53 papers	3,240 citations	186265 28 h-index	168389 53 g-index
56 all docs	56 docs citations	56 times ranked	4026 citing authors

#	Article	IF	Citations
1	Tissue-specific and repeat length-dependent somatic instability of the X-linked dystonia parkinsonism-associated CCCTCT repeat. Acta Neuropathologica Communications, 2022, 10, 49.	5.2	6
2	<scp>TAF1</scp> Transcripts and Neurofilament Light Chain as Biomarkers for Xâ€linked Dystoniaâ€Parkinsonism. Movement Disorders, 2021, 36, 206-215.	3.9	18
3	Isolated dystonia: clinical and genetic updates. Journal of Neural Transmission, 2021, 128, 405-416.	2.8	18
4	Rapid-Onset Dystonia-Parkinsonism Phenotype Consistency for a Novel Variant of ATP1A3 in Patients Across 3 Global Populations. Neurology: Genetics, 2021, 7, e562.	1.9	2
5	Genomewide Association Studies of <scp>LRRK2</scp> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	5.3	30
6	The dystonia gene THAP1 controls DNA double-strand break repair choice. Molecular Cell, 2021, 81, 2611-2624.e10.	9.7	16
7	Nonsteroidal <scp>Antiâ€inflammatory</scp> Use and <scp>LRRK2</scp> Parkinson's Disease Penetrance. Movement Disorders, 2020, 35, 1755-1764.	3.9	57
8	Isolated Cervical Dystonia: Management and Barriers to Care. Frontiers in Neurology, 2020, 11, 591418.	2.4	5
9	Defining research priorities in dystonia. Neurology, 2020, 94, 526-537.	1.1	26
10	Application of the Movement Disorder Society prodromal criteria in healthy G2019Sâ€LRRK2 carriers. Movement Disorders, 2018, 33, 966-973.	3.9	44
11	Progression in the LRRK2-Associated Parkinson Disease Population. JAMA Neurology, 2018, 75, 312.	9.0	109
12	Functional variants in the LRRK2 gene confer shared effects on risk for Crohnâ€™s disease and Parkinsonâ€™s disease. Science Translational Medicine, 2018, 10, .	12.4	273
13	Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers. Neurobiology of Aging, 2017, 58, 239.e1-239.e7.	3.1	6
14	Neuropsychiatric characteristics of GBA-associated Parkinson disease. Journal of the Neurological Sciences, 2016, 370, 63-69.	0.6	50
15	Expanded genetic screening panel for the Ashkenazi Jewish population. Genetics in Medicine, 2016, 18, 522-528.	2.4	33
16	REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers. Movement Disorders, 2015, 30, 1834-1839.	3.9	40
17	Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 106-110.	2.2	58
18	Interest in Genetic Testing in Ashkenazi Jewish Parkinson's Disease Patients and Their Unaffected Relatives. Journal of Genetic Counseling, 2015, 24, 238-246.	1.6	23

#	Article	IF	Citations
19	Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene. Movement Disorders, 2015, 30, 981-986.	3.9	52
20	Olfactory identification in <scp>LRRK</scp> 2 G2019S mutation carriers: a relevant marker?. Annals of Clinical and Translational Neurology, 2014, 1, 670-678.	3.7	43
21	Alternating Hemiplegia of Childhood With a de Novo Mutation in ATP1A3 and Changes in SLC2A1 Responsive to a Ketogenic Diet. Pediatric Neurology, 2014, 50, 377-379.	2.1	27
22	Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations. Movement Disorders, 2013, 28, 1966-1971.	3.9	131
23	The endophenotype and the phenotype: Temporal discrimination and adultâ€onset dystonia. Movement Disorders, 2013, 28, 1766-1774.	3.9	63
24	A Genome-Wide Scan of Ashkenazi Jewish Crohn's Disease Suggests Novel Susceptibility Loci. PLoS Genetics, 2012, 8, e1002559.	3.5	144
25	New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism. Parkinsonism and Related Disorders, 2012, 18, 737-741.	2.2	29
26	Evaluation of 22 genetic variants with Crohn's Disease risk in the Ashkenazi Jewish population: a case-control study. BMC Medical Genetics, 2011, 12, 63.	2.1	41
27	Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Movement Disorders, 2011, 26, 885-888.	3.9	31
28	Mood and cognition in leucineâ€rich repeat kinase 2 G2019S Parkinson's disease. Movement Disorders, 2011, 26, 1875-1880.	3.9	40
29	Genetics of Dystonia. Seminars in Neurology, 2011, 31, 441-448.	1.4	27
30	Gaucher disease ascertained through a Parkinson's center: Imaging and clinical characterization. Movement Disorders, 2010, 25, 1364-1372.	3.9	77
31	Screening of Brazilian families with primary dystonia reveals a novel THAP1 mutation and a de novo TOR1A GAG deletion. Movement Disorders, 2010, 25, 2854-2857.	3.9	19
32	Association of a Functional Polymorphism in the Cholesteryl Ester Transfer Protein (<emph) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 of the American Medical Association, 2010, 303, 150.	7.4	97
33	Substantia nigra hyperechogenicity in DYT6 dystonia: A pilot study. Parkinsonism and Related Disorders, 2010, 16, 420-422.	2.2	11
34	Responsiveness to levodopa in epsilonâ€sarcoglycan deletions. Movement Disorders, 2009, 24, 425-428.	3.9	43
35	TorsinB - perinuclear location and association with torsinA. Journal of Neurochemistry, 2004, 89, 1186-1194.	3.9	38
36	Mode of Inheritance and Susceptibility Locus for Restless Legs Syndrome, on Chromosome 12q. American Journal of Human Genetics, 2002, 71, 205-208.	6.2	44

#	Article	IF	Citations
37	Evidence That Paternal Expression of the Îμ-Sarcoglycan Gene Accounts for Reduced Penetrance in Myoclonus-Dystonia. American Journal of Human Genetics, 2002, 71, 1303-1311.	6.2	178
38	Molecular cloning and expression of rat torsinA in the normal and genetically dystonic (dt) rat. Molecular Brain Research, 2002, 101, 132-135.	2.3	16
39	Multiple founder effects in Japanese families with primary torsion dystonia harboring the GAG deletion in the TOR1A (DYT1) gene. Neurogenetics, 2002, 4, 105-106.	1.4	7
40	Inherited myoclonus-dystonia. Advances in Neurology, 2002, 89, 185-91.	0.8	10
41	Genetics of Primary Dystonia. Seminars in Neurology, 1999, 19, 271-280.	1.4	37
42	Analysis of bothTSC1 andTSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis. Human Mutation, 1999, 14, 412-422.	2.5	135
43	Exon scanning of the entireTSC2 gene for germline mutations in 40 unrelated patients with tuberous sclerosis. Human Mutation, 1998, 12, 408-416.	2.5	46
44	Exon scanning of the entire TSC2 gene for germline mutations in 40 unrelated patients with tuberous sclerosis. Human Mutation, 1998, 12, 408-416.	2.5	1
45	Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nature Genetics, 1995, 9, 152-159.	21.4	430
46	A High-Resolution Linkage Map of Human 9q34.1. Genomics, 1993, 17, 587-591.	2.9	25
47	Construction of a GT polymorphism map of human 9q. Genomics, 1992, 12, 229-240.	2.9	181
48	A radiation-reduced hybrid cell line containing 5 Mb/17 cM of human DNA from 9q34. Genomics, 1992, 13, 841-844.	2.9	15
49	Dopamine beta-hydroxylase gene excluded in four subtypes of hereditary dystonia. Human Genetics, 1991, 87, 311-316.	3.8	6
50	Human gene for torsion dystonia located on chromosome 9q32-q34. Neuron, 1989, 2, 1427-1434.	8.1	246
51	Partial linkage map of chromosome 13q in the region of the Wilson disease and retinoblastoma genes. Genetic Epidemiology, 1988, 5, 375-380.	1.3	10
52	Human monoamine oxidase gene (MAOA): Chromosome position (Xp21-p11) and DNA polymorphism. Genomics, 1988, 3, 53-58.	2.9	102
53	Linkage Analysis in a Family with Dominantly Inherited Torsion Dystonia: Exclusion of the Pro-Opiomelanocortin and Glutamic Acid Decarboxylase Genes and Other Chromosomal Regions Using DNA Polymorphisms. Journal of Neurogenetics, 1986, 3, 159-175.	1.4	24